SCHEMBL3933076

SCHEMBL3933076

CCOC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(CCCN(C)C)C(C)=O)cc1)c1ccc2c(c1)OCCO2

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 2/20 0.44
MAPK1 P28482 2/20 0.44
USP2 O75604 1/20 0.44
RAB9A P51151 4/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.39
GAA P10253 3/20 0.38
RXFP1 Q9HBX9 1/20 0.38
NPC1 O15118 3/20 0.37
KDM4E B2RXH2 4/20 0.37
TRPV1 Q8NER1 1/20 0.36
ALDH1A1 P00352 3/20 0.36
POLB P06746 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3933087 1.00 MAPT (0.44) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL3935317 0.96 MAPT (0.46) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL3935322 0.96 MAPT (0.46) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL3933011 0.96 MAPT (0.45) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL3933010 0.96 MAPT (0.45) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL5857760 0.91 RAB9A (0.47) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL5857755 0.91 RAB9A (0.47) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL3941941 0.90 MAPT (0.39) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL3941940 0.90 MAPT (0.39) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL3938725 0.88 MAOB (0.40) MAPTMEN1KMT2ALMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551830-B1 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA (DE) 2009-04-08 EP disclosed
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US disclosed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments CDK1, CDK2, CDK3 MAPT 1798/4885MEN1 1664/4885KMT2A 1839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.